DelfaGLP-1 Atlas

← Trials/Trial dossier/NCT02838589

EGRABINS1

CompletedPhase 2

The Effect of GLP-1 Receptor Agonist on Cerebral Blood Flow Velocity in Non-stroke Volunteers

The Effect of Glucagon-like Peptide 1 (GLP-1) Receptor Agonist on Cerebral Blood Flow Velocity in Non-Stroke Volunteers (EGRABINS1)

Lead sponsor

Christina Kruuse

Assets

Exenatide / GLP-1 / incretin class catch-all

Listed sites

1

Recruiting sites

—

Enrollment

30

actual

Study population

Healthy volunteers

Key I/E criterion

—

Primary endpoint

•Changes in the mean flow velocity in the middle cerebral arteries (mean flow velocity middle cerebral artery, cortical oxygenation nirs)

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT02838589
Org study IDH-16022532
Secondary ID2016-001221-14

Timeline

Milestones

Study first posted2016-07-20estimated
Last update posted2017-02-07estimated
Study start2016-08 (month precision)
Primary completion2017-02actual (month precision)
Study completion2017-02actual (month precision)

Assets

Investigational agents

ExenatideGLP-1 / incretin class catch-all

Study populations

Who this study enrolls

Healthy volunteers

Eligibility

Who can enroll

Minimum age50 Years
SexAll
Healthy volunteersAccepted

Inclusion criteria

•Person ≥ 50 years of age
•Has given written informed consent

Exclusion criteria

•Intracerebral haemorrhage
•Subdural / epidural hemorrhage
•subarachnoid haemorrhage
•previously major structural damage to the brain (eg. sequelae after large stroke or brain surgery)
•Diabetes type 1
•Diabetes type 2
•Known atrial fibrillation
•> 50% stenosis of internal carotid
•Known allergy to GLP-1 receptor agonists
•Hepatic impairment (ALT> 3 x upper normal limit)
•Renal impairment (eGFR <30 ml / min)
•Inflammatory bowel disease
•Previous pancreatitis
•Heart failure (NYHA class 3-4)
•Pregnancy or lactation
•Patient not expected to co-operate to the investigations
•Visualization of the middle cerebral artery bilaterally by transcranial doppler not possible

Endpoints (4)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Cardiometabolic biomarkers
3
Other (unclassified)
1

Cardiometabolic biomarkers

3 endpoints
Secondary/protocol endpoint

Changes in the endothelial reactivity measured by non-invasive pletysmography.

Time frame:3 hours

change from baseline, improvement

Secondary/protocol endpoint

Changes in the endothelial/inflammatory biomarkers in blood.

Time frame:3 hours

change from baseline, improvement

Secondary/protocol endpoint

Changes in the ankle-brachial index.

Time frame:3 hours

change from baseline, improvement

Other (unclassified)

1 endpoint
Primary/protocol endpoint/low confidence

Changes in the mean flow velocity in the middle cerebral arteries and in cortical oxigination .

Time frame:Up till 3 hours

change from baseline, descriptive

componentsmean flow velocity middle cerebral artery, cortical oxygenation nirs

Publications (1)

Bibliography

Records linked to this trial through ClinicalTrials.gov references, PubMed NCT search, and curated study seeds. 'Canonical' marks design/result papers; others are registry references or candidates.

Registry references + supporting bibliography

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2
Snapshot dateJuly 1, 2026
Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)
Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.